Search results
30 mar 2024 · The effect of ivermectin (IVM) in treating coronavirus disease 2019 (COVID-19) is still controversial, yet the drug has been widely used in the world. The aim of this review was to systematically evaluate the clinical outcomes of IVM in patients with COVID-19.
- Efficacy and safety of ivermectin for treatment of non-hospitalized ...
Five databases were searched until October 17, 2023, for...
- Efficacy and safety of ivermectin for treatment of non-hospitalized ...
1 sie 2024 · Five databases were searched until October 17, 2023, for randomized controlled trials (RCTs) in adult patients with COVID-19 treated with ivermectin against standard of care (SoC), placebo, or active drug. Primary outcomes were hospitalization, all-cause mortality, and adverse events (AEs).
Table. Evidence-base interventions for COVID-19 patients not requiring hospitalisation. Disease severity classification as per the Ministry of Health and Family Welfare, Government of India. PPE=personal protective equipment. SpO 2 =oxygen saturation. * Patients with mild symptoms and SpO 2 ≥94%. †. Patients with SpO 2 <94 and ≥90.
Ravikirti, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, Manjhi PK, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India.
28 cze 2021 · 28 June 2021. Article history. PDF. Split View. Cite. Permissions. Share. Abstract. Background. We systematically assessed benefits and harms of the use of ivermectin (IVM) in patients with coronavirus disease 2019 (COVID-19). Methods.
Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other...
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus dis-ease 2019 (Covid-19),...
